At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NUVB Nuvation Bio, Inc.
Pre-Mkt 05-13 04:37:27 EDT
4.84
+0.08
+1.68%
High4.88Low4.66Vol2.54M
Open4.75D1 Closing4.76Amplitude4.62%
Mkt Cap1.68BTradable Cap1.12BTotal Shares347.60M
T/O12.14MT/O Rate1.10%Tradable Shares231.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nuvation Bio says FDA accepts IBTROZI label update filing for ROS1+ NSCLC
Reuters  ·  05-06
Nuvation Bio says FDA accepts IBTROZI label update filing for ROS1+ NSCLC
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for Ibtrozi® (Taletrectinib) With Updated Duration of Response in Advanced Ros1-Positive Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  05-06
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for Ibtrozi® (Taletrectinib) With Updated Duration of Response in Advanced Ros1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc - FDA Accepts Supplemental Nda for Ibtrozi in Advanced Ros1+ Nsclc; Target Action Date Jan 4, 2027
THOMSON REUTERS  ·  05-06
Nuvation Bio Inc - FDA Accepts Supplemental Nda for Ibtrozi in Advanced Ros1+ Nsclc; Target Action Date Jan 4, 2027
Nuvation Bio participates in Bank of America Securities Healthcare Conference fireside chat
Reuters  ·  05-06
Nuvation Bio participates in Bank of America Securities Healthcare Conference fireside chat
Stock Track | Nuvation Bio Soars 5.33% Intraday on Positive Analyst Coverage and Maintained Price Targets
Stock Track  ·  05-05
Stock Track | Nuvation Bio Soars 5.33% Intraday on Positive Analyst Coverage and Maintained Price Targets
Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT), Evolus (EOLS) and Nuvation Bio (NUVB)
TIPRANKS  ·  05-05
Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT), Evolus (EOLS) and Nuvation Bio (NUVB)
Nuvation Bio Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Dow Jones  ·  05-05
Nuvation Bio Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Earnings Flash (NUVB) Nuvation Bio Posts Q1 EPS $0.01, vs. FactSet Est of $0.03 Loss
MT Newswires Live  ·  05-05
Earnings Flash (NUVB) Nuvation Bio Posts Q1 EPS $0.01, vs. FactSet Est of $0.03 Loss
Nuvation Bio publishes corporate presentation on IBTROZI ROS1 lung cancer drug```
Reuters  ·  05-05
Nuvation Bio publishes corporate presentation on IBTROZI ROS1 lung cancer drug```
Nuvation Bio Q1 net income turns positive on IBTROZI sales
Reuters  ·  05-05
Nuvation Bio Q1 net income turns positive on IBTROZI sales
Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate.
Benzinga  ·  05-05
Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate.
BRIEF-Nuvation Bio Q1 EPS USD 0.01
Reuters  ·  05-05
BRIEF-Nuvation Bio Q1 EPS USD 0.01
Nuvation Bio Q1 Pretax Profit USD 5.397 Million
THOMSON REUTERS  ·  05-05
Nuvation Bio Q1 Pretax Profit USD 5.397 Million
Press Release: Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Dow Jones  ·  05-05
Press Release: Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
BRIEF-Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (Ibtrozi®) As Recommended Option
Reuters  ·  04-27
BRIEF-Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (Ibtrozi®) As Recommended Option
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (Ibtrozi®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
THOMSON REUTERS  ·  04-27
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (Ibtrozi®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Earning Preview: Nuvation Bio, Inc. Q1 revenue is expected to increase by 14,240.76%, and institutional views are bullish
Earnings Agent  ·  04-27
Earning Preview: Nuvation Bio, Inc. Q1 revenue is expected to increase by 14,240.76%, and institutional views are bullish
Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI
TIPRANKS  ·  04-22
Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI
Nuvation Bio publishes corporate presentation on IBTROZI launch, oncology pipeline updates
Reuters  ·  04-22
Nuvation Bio publishes corporate presentation on IBTROZI launch, oncology pipeline updates
Nuvation Bio says pooled TRUST data show 49.7-month IBTROZI response duration
Reuters  ·  04-22
Nuvation Bio says pooled TRUST data show 49.7-month IBTROZI response duration

Introduction

Company Name.
Nuvation Bio, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .
Issue price:
--